| Year |
Citation |
Score |
| 2021 |
Diamant G, Simchony Goldman H, Gasri Plotnitsky L, Roitman M, Shiloach T, Globerson-Levin A, Eshhar Z, Haim O, Pencovich N, Grossman R, Ram Z, Volovitz I. T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields. Journal of Immunology (Baltimore, Md. : 1950). PMID 34215656 DOI: 10.4049/jimmunol.2100100 |
0.791 |
|
| 2021 |
Levin AG, Rivière I, Eshhar Z, Sadelain M. CAR T cells: building on the CD19 paradigm. European Journal of Immunology. PMID 34196410 DOI: 10.1002/eji.202049064 |
0.44 |
|
| 2021 |
Rousso-Noori L, Mastandrea I, Talmor S, Waks T, Globerson Levin A, Haugas M, Teesalu T, Alvarez-Vallina L, Eshhar Z, Friedmann-Morvinski D. P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications. 12: 3615. PMID 34127674 DOI: 10.1038/s41467-021-23817-2 |
0.441 |
|
| 2020 |
Globerson Levin A, Rawet Slobodkin M, Waks T, Horn G, Ninio-Many L, Deshet Unger N, Ohayon Y, Suliman S, Cohen Y, Tartakovsky B, Naparstek E, Avivi I, Eshhar Z. Treatment of Multiple Myeloma using Chimeric Antigen Receptor T Cells with Dual Specificity. Cancer Immunology Research. PMID 33008840 DOI: 10.1158/2326-6066.CIR-20-0118 |
0.42 |
|
| 2020 |
Szoor A, Toth G, Zsebik B, Szabo V, Eshhar Z, Abken H, Vereb G. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Letters. PMID 32289441 DOI: 10.1016/j.canlet.2020.04.008 |
0.461 |
|
| 2020 |
Globerson Levin A, Kronik N, Shiloach T, Waks T, Eshhar Z, Vainstein V. Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach. Cancer Immunology, Immunotherapy : Cii. PMID 32130452 DOI: 10.1007/S00262-020-02516-9 |
0.463 |
|
| 2019 |
Diamant G, Simchony H, Shiloach T, Globerson-Levin A, Gasri Plotnitsky L, Eshhar Z, Pencovich N, Grossman R, Ram Z, Volovitz I. P12.05 Evaluating the compatibility of tumor treating electric fields with key antitumoral immune functions Neuro-Oncology. 21: iii60-iii60. DOI: 10.1093/neuonc/noz126.216 |
0.797 |
|
| 2018 |
Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29306001 DOI: 10.1016/J.Nano.2017.12.011 |
0.779 |
|
| 2018 |
Diamant G, Simchony H, Shiloach T, Globerson-Levin A, Eshhar Z, Grossman R, Ram Z, Volovitz I. IMMU-71. EVALUATING THE COMPATIBILITY OF TUMOR TREATING ELECTRIC FIELDS WITH KEY ANTI-TUMORAL T CELL FUNCTIONS Neuro-Oncology. 20: vi137-vi138. DOI: 10.1093/Neuonc/Noy148.574 |
0.77 |
|
| 2016 |
Gross G, Eshhar Z. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annual Review of Pharmacology and Toxicology. 56: 59-83. PMID 26738472 DOI: 10.1146/Annurev-Pharmtox-010814-124844 |
0.552 |
|
| 2016 |
Gross G, Eshhar Z. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy Annual Review of Pharmacology and Toxicology. 56: 59-83. DOI: 10.1146/annurev-pharmtox-010814-124844 |
0.445 |
|
| 2015 |
Bot A, Brewer JE, Eshhar Z, Frankel SR, Hickman E, Jungbluth AA, Morgan R, Peretz Y, Radvanyi L, Ramos CA, Robbins PF, Wucherpfennig KW. Target discovery for T cell therapy: next steps to advance Immunotherapies Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/S40425-015-0061-5 |
0.396 |
|
| 2014 |
Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. Journal of Immunology (Baltimore, Md. : 1950). 193: 5733-43. PMID 25362181 DOI: 10.4049/Jimmunol.1301769 |
0.515 |
|
| 2014 |
Eshhar Z. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Human Gene Therapy. 25: 773-8. PMID 25244568 DOI: 10.1089/Hum.2014.2532 |
0.455 |
|
| 2014 |
Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1018-28. PMID 24686242 DOI: 10.1038/Mt.2014.41 |
0.47 |
|
| 2014 |
Eshhar Z, Waks T, Gross G. The emergence of T-Bodies/CAR T cells Cancer Journal (United States). 20: 123-126. PMID 24667957 DOI: 10.1097/PPO.0000000000000027 |
0.435 |
|
| 2014 |
Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer Expert Opinion On Biological Therapy. 14: 947-954. PMID 24661086 DOI: 10.1517/14712598.2014.900540 |
0.517 |
|
| 2014 |
Globerson-Levin A, Waks T, Eshhar Z. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1029-38. PMID 24572294 DOI: 10.1038/Mt.2014.28 |
0.797 |
|
| 2014 |
Friedmann-Morvinski D, Waks T, Marcus A, Eshhar Z. Adoptive Cell Therapy of Systemic Metastases Using erbB-2-Specific T Cells Redirected with a Chimeric Antibody-Based Receptor Current Cancer Research. 12: 107-122. DOI: 10.1007/978-1-4614-8809-5_7 |
0.404 |
|
| 2013 |
Agemy L, Kela I, Waks T, Pfeffer RM, Bar-Shira A, Orr-Urtreger A, Domany E, Eshhar Z. Gene Expression Profiles Predict Sensitivity of Prostate Cancer to Radiotherapy Journal of Cancer Therapy. 4: 11-26. DOI: 10.4236/Jct.2013.44A003 |
0.332 |
|
| 2013 |
Eshhar Z. The T-body approach combining antibody specificity with T cell activity for adoptive vaccination of cancer Journal of Vaccines and Vaccination. DOI: 10.4172/2157-7560.S1.016 |
0.557 |
|
| 2012 |
Chmielewski M, Maliar A, Eshhar Z, Abken H. CAR's made it to the pancreas. Oncoimmunology. 1: 1387-1389. PMID 23243602 DOI: 10.4161/Onci.22195 |
0.79 |
|
| 2012 |
Fishler R, Artzy-Schnirman A, Peer E, Wolchinsky R, Brener R, Waks T, Eshhar Z, Reiter Y, Sivan U. Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions. Nano Letters. 12: 4992-6. PMID 22900991 DOI: 10.1021/Nl302619P |
0.461 |
|
| 2012 |
Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology. 143: 1375-84.e1-5. PMID 22819865 DOI: 10.1053/J.Gastro.2012.07.017 |
0.808 |
|
| 2012 |
Maliar A, Servais C, Waks T, Eshhar Z. 1060 Redirecting Effector Lymphocytes for Adoptive Cell Therapy of Pancreatic Adenocarcinoma in Mice Gastroenterology. 142: S-187. DOI: 10.1016/S0016-5085(12)60703-3 |
0.76 |
|
| 2011 |
Marcus A, Eshhar Z. Tumor-specific allogeneic cells for cancer therapy. Expert Opinion On Biological Therapy. 11: 1551-4. PMID 21995504 DOI: 10.1517/14712598.2011.628934 |
0.477 |
|
| 2011 |
Artzy-Schnirman A, Blat D, Talmon Y, Fishler R, Gertman D, Oren R, Wolchinsky R, Waks T, Benhar I, Eshhar Z, Sivan U, Reiter Y. Electrically controlled molecular recognition harnessed to activate a cellular response. Nano Letters. 11: 4997-5001. PMID 21985491 DOI: 10.1021/Nl202971R |
0.413 |
|
| 2011 |
Marcus A, Eshhar Z. Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer. Oncotarget. 2: 525-6. PMID 21719916 DOI: 10.18632/Oncotarget.300 |
0.554 |
|
| 2011 |
Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood. 118: 975-83. PMID 21653325 DOI: 10.1182/Blood-2011-02-334284 |
0.537 |
|
| 2010 |
Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium. Development of adoptive cell therapy for cancer: a clinical perspective. Human Gene Therapy. 21: 665-72. PMID 20408760 DOI: 10.1089/Hum.2010.086 |
0.492 |
|
| 2010 |
Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. Current Opinion in Molecular Therapeutics. 12: 55-63. PMID 20140817 |
0.472 |
|
| 2009 |
Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 183: 5563-74. PMID 19843940 DOI: 10.4049/Jimmunol.0900447 |
0.428 |
|
| 2009 |
Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology. 136: 1721-31. PMID 19208357 DOI: 10.1053/J.Gastro.2009.01.049 |
0.478 |
|
| 2008 |
Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology. 134: 2014-24. PMID 18424268 DOI: 10.1053/J.Gastro.2008.02.060 |
0.451 |
|
| 2008 |
Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z. Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate. 68: 530-9. PMID 18247403 DOI: 10.1002/Pros.20702 |
0.301 |
|
| 2008 |
Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handbook of Experimental Pharmacology. 329-42. PMID 18071952 DOI: 10.1007/978-3-540-73259-4_14 |
0.447 |
|
| 2006 |
Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6106-15. PMID 17062687 DOI: 10.1158/1078-0432.Ccr-06-1183 |
0.399 |
|
| 2006 |
Papo N, Seger D, Makovitzki A, Kalchenko V, Eshhar Z, Degani H, Shai Y. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Research. 66: 5371-8. PMID 16707464 DOI: 10.1158/0008-5472.Can-05-4569 |
0.367 |
|
| 2006 |
Friedmann-Morvinski D, Waks T, Eshhar Z. 264. Immune Gene-Therapy of Cancer Using Redirected Naïve or Effector Lymphocytes Molecular Therapy. 13: S101. DOI: 10.1016/J.Ymthe.2006.08.318 |
0.321 |
|
| 2006 |
Agemy L, Eshhar Z, Kela I, Domany E, Orr-Urtreger A, Bar-Shira A, Raphael Pfeffer M. 1017. Genetic Predisposition of the Sensitivity of Prostate Cancer to Radiatherapy Molecular Therapy. 13: S391. DOI: 10.1016/J.Ymthe.2006.08.1111 |
0.309 |
|
| 2006 |
Friedmann-Morvinski D, Eshhar Z. Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity Update On Cancer Therapeutics. 1: 25-32. DOI: 10.1016/J.Uct.2006.04.005 |
0.472 |
|
| 2005 |
Eshhar Z, Waks T, Pinthus J. Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells. Discovery Medicine. 5: 259-64. PMID 20704885 |
0.303 |
|
| 2005 |
Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 105: 3087-93. PMID 15626734 DOI: 10.1182/Blood-2004-09-3737 |
0.51 |
|
| 2004 |
Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. The Journal of Clinical Investigation. 114: 1774-81. PMID 15599402 DOI: 10.1172/Jci22284 |
0.436 |
|
| 2004 |
Pinthus JH, Fridman E, Dekel B, Goldberg I, Kaufman-Francis K, Eshhar Z, Harmelin A, Rechavi G, Mor O, Ramon J, Mor Y. ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. The Journal of Urology. 172: 1644-8. PMID 15371781 DOI: 10.1097/01.Ju.0000140139.91993.A0 |
0.388 |
|
| 2004 |
Papo N, Braunstein A, Eshhar Z, Shai Y. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Research. 64: 5779-86. PMID 15313920 DOI: 10.1158/0008-5472.Can-04-1438 |
0.323 |
|
| 2004 |
Plaks V, Koudinova N, Nevo U, Pinthus JH, Kanety H, Eshhar Z, Ramon J, Scherz A, Neeman M, Salomon Y. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: A biphasic apparent diffusion coefficient change as potential early MRI response marker Neoplasia. 6: 224-233. PMID 15153334 DOI: 10.1593/Neo.3352 |
0.313 |
|
| 2003 |
Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Research. 63: 2470-6. PMID 12750268 |
0.372 |
|
| 2003 |
Levit-Binnun N, Lindner AB, Zik O, Eshhar Z, Moses E. Quantitative detection of protein arrays. Analytical Chemistry. 75: 1436-41. PMID 12659207 DOI: 10.1021/Ac0261350 |
0.617 |
|
| 2003 |
Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. International Journal of Cancer. 104: 782-9. PMID 12640688 DOI: 10.1002/Ijc.11002 |
0.374 |
|
| 2002 |
Lindner AB, Kim SH, Schindler DG, Eshhar Z, Tawfik DS. Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis. Journal of Molecular Biology. 320: 559-72. PMID 12096909 DOI: 10.1016/S0022-2836(02)00418-7 |
0.646 |
|
| 2001 |
Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. Journal of Immunological Methods. 248: 67-76. PMID 11223069 DOI: 10.1016/S0022-1759(00)00343-4 |
0.533 |
|
| 2000 |
Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Therapy. 7: 1369-77. PMID 10981663 DOI: 10.1038/Sj.Gt.3301253 |
0.462 |
|
| 2000 |
Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Therapy. 7: 284-91. PMID 10770638 DOI: 10.1038/Sj.Cgt.7700121 |
0.508 |
|
| 1999 |
Lindner AB, Eshhar Z, Tawfik DS. Conformational changes affect binding and catalysis by ester-hydrolysing antibodies. Journal of Molecular Biology. 285: 421-30. PMID 9878416 DOI: 10.1006/Jmbi.1998.2309 |
0.658 |
|
| 1999 |
Gigant B, Golinelli B, Charbonnier J, Eshhar Z, Green B, Knossow M. Structures of Esterase-Like Catalytic Antibodies Phosphorus, Sulfur, and Silicon and the Related Elements. 144: 121-124. DOI: 10.1080/10426509908546197 |
0.328 |
|
| 1998 |
Fitzer-Attas CJ, Eshhar Z. Tyrosine kinase chimeras for antigen-selective T-body therapy. Advanced Drug Delivery Reviews. 31: 171-182. PMID 10837624 DOI: 10.1016/S0169-409X(97)00100-2 |
0.466 |
|
| 1998 |
Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunology, Immunotherapy : Cii. 45: 131-6. PMID 9435856 DOI: 10.1007/S002620050415 |
0.559 |
|
| 1997 |
Kim SH, Schindler DG, Lindner AB, Tawfik DS, Eshhar Z. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Molecular Immunology. 34: 891-906. PMID 9464525 DOI: 10.1016/S0161-5890(97)00096-5 |
0.667 |
|
| 1997 |
Gigant B, Charbonnier JB, Golinelli-Pimpaneau B, Zemel RR, Eshhar Z, Green BS, Knossow M. Mechanism of inactivation of a catalytic antibody by p-nitrophenyl esters European Journal of Biochemistry. 246: 471-476. PMID 9208940 DOI: 10.1111/J.1432-1033.1997.T01-1-00471.X |
0.331 |
|
| 1997 |
Tawfik DS, Lindner AB, Chap R, Eshhar Z, Green BS. Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten. European Journal of Biochemistry / Febs. 244: 619-26. PMID 9119032 DOI: 10.1111/J.1432-1033.1997.00619.X |
0.622 |
|
| 1997 |
Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. The Journal of Biological Chemistry. 272: 8551-7. PMID 9079685 DOI: 10.1074/Jbc.272.13.8551 |
0.432 |
|
| 1997 |
Charbonnier JB, Golinelli-Pimpaneau B, Gigant B, Tawfik DS, Chap R, Schindler DG, Kim SH, Green BS, Eshhar Z, Knossow M. Structural convergence in the active sites of a family of catalytic antibodies. Science (New York, N.Y.). 275: 1140-2. PMID 9027317 DOI: 10.1126/Science.275.5303.1140 |
0.34 |
|
| 1996 |
Gross G, Levy S, Levy R, Waks T, Eshhar Z. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochemical Society Transactions. 23: 1079-82. PMID 8654685 DOI: 10.1042/Bst0231079 |
0.315 |
|
| 1996 |
Lustgarten J, Waks T, Eshhar Z. Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Molecular Immunology. 33: 245-51. PMID 8649445 DOI: 10.1016/0161-5890(95)00141-7 |
0.4 |
|
| 1996 |
Charbonnier JB, Carpenter E, Gigant B, Golinelli-Pimpaneau B, Eshhar Z, Green BS, Knossow M. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies. Proceedings of the National Academy of Sciences of the United States of America. 92: 11721-5. PMID 8524836 DOI: 10.1073/Pnas.92.25.11721 |
0.333 |
|
| 1996 |
Knossow M, Charbonnier J, Gigant B, Golinelli B, Tawfik D, Eshhar Z, Green BS. Structural studies of catalytic antibodies with esterase activity Acta Crystallographica Section a Foundations of Crystallography. 52: C216-C216. DOI: 10.1107/S0108767396090708 |
0.331 |
|
| 1995 |
Tawfik DS, Chap R, Green BS, Sela M, Eshhar Z. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: Is there a linkage to autoimmunity? Proceedings of the National Academy of Sciences of the United States of America. 92: 2145-2149. PMID 7892238 DOI: 10.1073/Pnas.92.6.2145 |
0.381 |
|
| 1995 |
Lustgarten J, Eshhar Z. Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes. European Journal of Immunology. 25: 2985-91. PMID 7589102 DOI: 10.1002/Eji.1830251041 |
0.497 |
|
| 1995 |
Eshhar Z, Gross G, Waks T, Lustgarten J, Bach N, Ratner A, Treisman J, Schindler DG. T-bodies: Chimeric T-cell receptors with antibody-type specificity Methods: a Companion to Methods in Enzymology. 8: 133-142. DOI: 10.1006/Meth.1995.9993 |
0.531 |
|
| 1994 |
Zemel R, Schindler DG, Tawfik DS, Eshhar Z, Green BS. Differences in the biochemical properties of esterolytic antibodies correlate with structural diversity. Molecular Immunology. 31: 127-37. PMID 8309476 DOI: 10.1016/0161-5890(94)90085-X |
0.355 |
|
| 1994 |
Tawfik DS, Chap R, Eshhar Z, Green BS. Ph on-off switching of antibody-hapten binding by site-specificchemical modification of tyrosine Protein Engineering, Design and Selection. 7: 431-434. PMID 8177892 DOI: 10.1093/Protein/7.3.431 |
0.302 |
|
| 1994 |
Golinelli-Pimpaneau B, Gigant B, Bizebard T, Navaza J, Saludjian P, Zemel R, Tawfik D, Eshhar Z, Green B, Knossow M. Crystal structure of a catalytic antibody Fab with esterase- like activity Structure. 2: 175-183. PMID 8069632 DOI: 10.1016/S0969-2126(00)00019-8 |
0.356 |
|
| 1994 |
Tawfik DS, Eshhar Z, Green BS. Catalytic antibodies: A critical assessment Molecular Biotechnology. 1: 87-103. PMID 7859154 DOI: 10.1007/Bf02821512 |
0.331 |
|
| 1994 |
Bach NL, Waks T, Schindler DG, Eshhar Z. Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophysics. 24: 229-36. PMID 7736527 DOI: 10.1007/BF02789233 |
0.372 |
|
| 1993 |
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America. 90: 720-4. PMID 8421711 DOI: 10.1073/Pnas.90.2.720 |
0.55 |
|
| 1993 |
Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. The Journal of Experimental Medicine. 178: 361-6. PMID 8315392 DOI: 10.1084/Jem.178.1.361 |
0.436 |
|
| 1993 |
Tawfik DS, Green BS, Chap R, Sela M, Eshhar Z. catELISA: A facile general route to catalytic antibodies Proceedings of the National Academy of Sciences of the United States of America. 90: 373-377. PMID 7678455 DOI: 10.1073/Pnas.90.2.373 |
0.337 |
|
| 1993 |
Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 6: 3370-8. PMID 1464371 DOI: 10.1096/Fasebj.6.15.1464371 |
0.554 |
|
| 1993 |
Eisenstein M, Schindler DS, Zemel R, Green BS, Eshhar Z. Models for catalytic antibodies: a tool for understanding their mechanism of action Acta Crystallographica Section a Foundations of Crystallography. 49: c151-c151. DOI: 10.1107/S0108767378095690 |
0.303 |
|
| 1993 |
Tawfik DS, Eshhar Z, Green BS. From Phosphonates to Catalytic Antibodies. A Novel Route to Phosphonoester Transition State Analogs and Haptens Phosphorus, Sulfur, and Silicon and the Related Elements. 76: 123-126. DOI: 10.1080/10426509308032374 |
0.31 |
|
| 1992 |
Glikson M, Arad-Yellin R, Ghozi M, Raveh L, Green BS, Eshhar Z. Characterization of soman-binding antibodies raised against soman analogs. Molecular Immunology. 29: 903-10. PMID 1635561 DOI: 10.1016/0161-5890(92)90128-K |
0.358 |
|
| 1992 |
Tawfik DS, Green BS, Eshhar Z. Detection of catalytic monoclonal antibodies Analytical Biochemistry. 202: 35-39. PMID 1621985 DOI: 10.1016/0003-2697(92)90201-H |
0.358 |
|
| 1991 |
Lustgarten J, Waks T, Eshhar Z. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex. European Journal of Immunology. 21: 2507-15. PMID 1915555 DOI: 10.1002/Eji.1830211030 |
0.39 |
|
| 1991 |
Lubin I, Faktorowich Y, Lapidot T, Gan Y, Eshhar Z, Gazit E, Levite M, Reisner Y. Engraftment and development of human T and B cells in mice after bone marrow transplantation Science. 252: 427-431. PMID 1826797 DOI: 10.1126/Science.1826797 |
0.355 |
|
| 1991 |
Nissim A, Jouvin MH, Eshhar Z. Mapping of the high affinity Fc epsilon receptor binding site to the third constant region domain of IgE. The Embo Journal. 10: 101-107. DOI: 10.1002/J.1460-2075.1991.Tb07925.X |
0.301 |
|
| 1990 |
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America. 86: 10024-8. PMID 2513569 DOI: 10.1073/Pnas.86.24.10024 |
0.469 |
|
| 1990 |
Tawfik DS, Zemel RR, Arad-Yellin R, Green BS, Eshhar Z. Simple method for selecting catalytic monoclonal antibodies that exhibit turnover and specificity Biochemistry. 29: 9916-9921. PMID 2271630 DOI: 10.1021/Bi00494A023 |
0.367 |
|
| 1990 |
Varon D, Linder S, Gembom E, Guedg L, Langbeheim H, Berrebi A, Eshhar Z. Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament's determinant common to vimentin and desmin. Clinical Immunology and Immunopathology. 54: 454-68. PMID 1689230 DOI: 10.1016/0090-1229(90)90058-X |
0.401 |
|
| 1989 |
Novick D, Eshhar Z, Revel M, Mory Y. Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity. Hybridoma. 8: 561-7. PMID 2680901 DOI: 10.1089/Hyb.1989.8.561 |
0.359 |
|
| 1989 |
Novick D, Fischer DG, Reiter Z, Eshhar Z, Rubinstein M. Monoclonal antibodies to the human interferon-gamma receptor: blocking of the biological activities of interferon-gamma and purification of the receptor. Journal of Interferon Research. 9: 315-28. PMID 2526186 DOI: 10.1089/Jir.1989.9.315 |
0.388 |
|
| 1989 |
Kwon BS, Kestler DP, Eshhar Z, Oh KO, Wakulchik M. Expression characteristics of two potential T cell mediator genes. Cellular Immunology. 121: 414-22. PMID 2500256 DOI: 10.1016/0008-8749(89)90040-3 |
0.467 |
|
| 1989 |
Schwarzbaum S, Nissim A, Alkalay I, Ghozi MC, Schindler DG, Bergman Y, Eshhar Z. Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions. European Journal of Immunology. 19: 1015-23. PMID 2473907 DOI: 10.1002/Eji.1830190610 |
0.335 |
|
| 1988 |
Baniyash M, Kehry M, Eshhar Z. Anti-IgE monoclonal antibodies directed at the Fc epsilon receptor binding site. Molecular Immunology. 25: 705-11. PMID 2460756 DOI: 10.1016/0161-5890(88)90106-X |
0.38 |
|
| 1987 |
Baniyash M, Eshhar Z. Anti-anti-IgE idiotypic antibodies mimic IgE in their binding to the Fc epsilon receptor. European Journal of Immunology. 17: 1337-42. PMID 2443366 DOI: 10.1002/Eji.1830170918 |
0.387 |
|
| 1986 |
Berrebi A, Eshhar Z, Linder S, Guedj L, Avraham H. RAB-1: a new monoclonal antibody to leukemic hairy cells. Leukemia Research. 10: 1071-8. PMID 3531732 DOI: 10.1016/0145-2126(86)90051-2 |
0.488 |
|
| 1986 |
Livneh A, Avraham H, Elias D, Sack J, Cohen IR, Eshhar Z. A human monoclonal antibody to insulin. Diabetes. 35: 68-73. PMID 3510142 DOI: 10.2337/Diab.35.1.68 |
0.317 |
|
| 1986 |
Firer MA, Eshhar Z. T cell derived IgE binding factors inhibit IgE-specific rosettes on basophilic leukaemic cells and lymphocytes. Immunology Letters. 13: 1-5. PMID 2428738 DOI: 10.1016/0165-2478(86)90116-1 |
0.332 |
|
| 1985 |
Hahn T, Toker L, Budilovsky S, Aderka D, Eshhar Z, Wallach D. Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proceedings of the National Academy of Sciences of the United States of America. 82: 3814-8. PMID 3889916 DOI: 10.1073/Pnas.82.11.3814 |
0.426 |
|
| 1985 |
Novick D, Fischer DG, Chernajovsky Y, Revel M, Rubinstein M, Eshhar Z, Mory Y. Monoclonal Antibodies for Purification and RIA of Natural and Recombinant Human Interferon-α, -β And-γ Protides of the Biological Fluids. 32: 945-948. DOI: 10.1016/B978-0-08-031739-7.50232-9 |
0.325 |
|
| 1984 |
Hadas E, Hurwitz E, Eshhar Z. Identification of a surface antigen, common to murine lung and lewis lung carcinoma, by monoclonal antibody International Journal of Cancer. 33: 369-374. PMID 6365802 DOI: 10.1002/Ijc.2910330315 |
0.411 |
|
| 1984 |
Baniyash M, Eshhar Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. European Journal of Immunology. 14: 799-807. PMID 6207029 DOI: 10.1002/Eji.1830140907 |
0.426 |
|
| 1984 |
Meiri H, Zeitoun I, Grunhagen HH, Lev-Ram V, Eshhar Z, Schlessinger J. Monoclonal antibodies associated with sodium channel block nerve impulse and stain nodes of Ranvier. Brain Research. 310: 168-73. PMID 6089966 DOI: 10.1016/0006-8993(84)90023-4 |
0.313 |
|
| 1984 |
Eshhar Z, Ben-Izhak R, Ariel N, Arnon R. Differences Amoung Individual CEA Preparations and Carcinomas of Different Origin as Detected by Monoclonal Anti-CEA Antibodies Protides of the Biological Fluids. 31: 929-932. DOI: 10.1016/B978-0-08-030764-0.50211-1 |
0.369 |
|
| 1983 |
Kohen F, Lichter S, Eshhar Z, Lindner HR. Preparation of monoclonal antibodies able to discriminate between testosterone and 5 alpha-dihydrotestosterone. Steroids. 39: 453-9. PMID 7179353 DOI: 10.1016/0039-128X(82)90069-1 |
0.412 |
|
| 1983 |
De Baetselier P, Gorelik E, Eshhar Z, Ron Y, Katsav S, Feldman M, Segal S. Organ-specific homing of B-cell hybridomas. Advances in Experimental Medicine and Biology. 149: 179-85. PMID 6983212 DOI: 10.1007/978-1-4684-9066-4_24 |
0.424 |
|
| 1983 |
Kaufmann Y, Golstein P, Pierres M, Springer TA, Eshhar Z. LFA-1 but not Lyt-2 is associated with killing activity of cytotoxic T lymphocyte hybridomas. Nature. 300: 357-60. PMID 6983035 DOI: 10.1038/300357A0 |
0.415 |
|
| 1983 |
Bahr GM, Eshhar Z, Ben-Yitzhak R, Modabber FZ, Arnon R, Sela M, Chedid L. Monoclonal antibodies to the synthetic adjuvant muramyl dipeptide: characterization of the specificity. Molecular Immunology. 20: 745-52. PMID 6888382 DOI: 10.1016/0161-5890(83)90052-4 |
0.374 |
|
| 1983 |
Novick D, Eshhar Z, Gigi O, Marks Z, Revel M, Rubinstein M. Affinity chromatography of human fibroblast interferon (IFN-beta 1) by monoclonal antibody columns. The Journal of General Virology. 905-10. PMID 6834009 DOI: 10.1099/0022-1317-64-4-905 |
0.313 |
|
| 1983 |
Eshhar Z, Gigi O, Givol D, Ben-Neriah Y. Monoclonal anti-VH antibodies recognize a common VH determinant expressed on immunoglobulin heavy chains from various species. European Journal of Immunology. 13: 533-40. PMID 6191996 DOI: 10.1002/Eji.1830130704 |
0.395 |
|
| 1983 |
Eshhar Z, Novik D, Gigi O, Marks Z, Friedlander Y, Revel M, Rubinstein M. Monoclonal Antibodies to Human Leukocyte and Fibroblast Interferon Protides of the Biological Fluids. 30: 491-494. DOI: 10.1016/B978-0-08-029815-3.50111-2 |
0.323 |
|
| 1983 |
Novick D, Eshhar Z, Fischer D, Friedlander J, Rubinstein M. Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay. The Embo Journal. 2: 1527-1530. DOI: 10.1002/J.1460-2075.1983.Tb01618.X |
0.364 |
|
| 1983 |
Horowitz S, Tarrab-Hazdai R, Eshhar Z, Arnon R. Anti-schistosome monoclonal antibodies of different isotypes-correlation with cytotoxicity. The Embo Journal. 2: 193-198. DOI: 10.1002/J.1460-2075.1983.Tb01404.X |
0.417 |
|
| 1982 |
Golstein P, Pierres M, Schmitt-Verhulst AM, Luciani MF, Buferne M, Eshhar Z, Kaufmann Y. Functional relationships of lymphocyte membrane structures probed with cytolysis and/or proliferation-inhibiting H35-27.9 and H35-89.9 monoclonal antibodies. Advances in Experimental Medicine and Biology. 146: 487-503. PMID 6980572 DOI: 10.1007/978-1-4684-8959-0_29 |
0.468 |
|
| 1982 |
Eshhar Z, Waks T, Oren T, Berke G, Kaufmann Y. Cytotoxic T cell hybridomas: generation and characterization Current Topics in Microbiology and Immunology. 100: 11-18. PMID 6980088 |
0.372 |
|
| 1982 |
Davidson I, Katzav S, Ungar-Waron H, Eshhar Z, Haimovich J, Trainin Z. Somatic cell hybridization between bovine leukemia virus-infected lymphocytes and murine plasma cell tumors: cell fusion studies with bovine cells. Molecular Immunology. 19: 893-9. PMID 6289087 DOI: 10.1016/0161-5890(82)90355-8 |
0.361 |
|
| 1982 |
Scherson T, Geiger B, Eshhar Z, Littauer UZ. Mapping of distinct structural domains on microtubule-associated protein 2 by monoclonal antibodies. European Journal of Biochemistry / Febs. 129: 295-302. PMID 6185336 DOI: 10.1111/J.1432-1033.1982.Tb07052.X |
0.341 |
|
| 1982 |
Golstein P, Goridis C, Schmitt-Verhulst AM, Hayot B, Pierres A, van Agthoven A, Kaufmann Y, Eshhar Z, Pierres M. Lymphoid cell surface interaction structures detected using cytolysis-inhibiting monoclonal antibodies. Immunological Reviews. 68: 5-42. PMID 6184306 DOI: 10.1111/J.1600-065X.1982.Tb01058.X |
0.466 |
|
| 1982 |
Eshhar Z, Waks T, Zinger H, Mozes E. T cell hybridomas producing antigen-specific factors express heavy-chain variable-region determinants. Current Topics in Microbiology and Immunology. 100: 103-9. PMID 6178554 DOI: 10.1007/978-3-642-68586-6_12 |
0.326 |
|
| 1982 |
Apte RN, Eshhar Z, Löwy I, Zinger H, Mozes E. Characteristics of a poly(LTyr,LGlu)-poly(DLAla)--poly(LLys)-specific helper factor derived from a T cell hybridoma. European Journal of Immunology. 11: 931-6. PMID 6173232 DOI: 10.1002/Eji.1830111115 |
0.413 |
|
| 1982 |
Kohen F, Lindner HR, Eshhar Z. Production of Monoclonal Antibodies to Steroid Hormones Protides of the Biological Fluids. 29: 823-826. DOI: 10.1016/B978-0-08-027988-6.50192-0 |
0.362 |
|
| 1982 |
Gigi O, Geiger B, Eshhar Z, Moll R, Schmid E, Winter S, Schiller D, Franke W. Detection of a cytokeratin determinant common to diverse epithelial cells by a broadly cross-reacting monoclonal antibody. The Embo Journal. 1: 1429-1437. DOI: 10.1002/J.1460-2075.1982.Tb01334.X |
0.415 |
|
| 1981 |
Kaufmann Y, Berke G, Eshhar Z. Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro Proceedings of the National Academy of Sciences of the United States of America. 78: 2502-2506. PMID 6972538 DOI: 10.1073/Pnas.78.4.2502 |
0.376 |
|
| 1981 |
Schreiber AB, Lax I, Yarden Y, Eshhar Z, Schlessinger J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proceedings of the National Academy of Sciences of the United States of America. 78: 7535-9. PMID 6278478 DOI: 10.1073/Pnas.78.12.7535 |
0.413 |
|
| 1981 |
Horwitz B, Kupfer H, Eshhar Z, Geiger B. Reorganization of arrays of prekeratin filaments during mitosis. Immunofluorescence microscopy with multiclonal and monoclonal prekeratin antibodies. Experimental Cell Research. 134: 281-90. PMID 6168474 DOI: 10.1016/0014-4827(81)90427-4 |
0.387 |
|
| 1981 |
Baetselier PD, Gorelik E, Eshhar Z, Ron Y, Katzav S, Feldman M, Segal S. Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmacytoma cells. Journal of the National Cancer Institute. 67: 1079-1087. DOI: 10.1093/Jnci/67.5.1079 |
0.331 |
|
| 1980 |
Fuchs S, Bartfeld D, Eshhar Z, Feingold C, Mochly-Rosen D, Novick D, Schwartz M, Tarrab-Hazdai R. Immune regulation of experimental myasthenia Journal of Neurology, Neurosurgery and Psychiatry. 43: 634-643. PMID 7400824 DOI: 10.1136/Jnnp.43.7.634 |
0.342 |
|
| 1980 |
Kohen F, Kim JB, Lindner HR, Eshhar Z, Green B. Monoclonal immunoglobulin G augments hydrolysis of an ester of the homologous hapten: an esterase-like activity of the antibody-containing site? Febs Letters. 111: 427-31. PMID 7358185 DOI: 10.1016/0014-5793(80)80842-8 |
0.34 |
|
| 1980 |
Strassmann G, Eshhar Z, Mozes E. Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGlu)-poly(DLAla)--poly(LLys). II. Evidence for a T-T-cell collaboration in delayed-type hypersensitivity responses and for a T-cell defect at the efferent phase in nonresponder H-2k mice. The Journal of Experimental Medicine. 151: 628-36. PMID 6766982 DOI: 10.1084/Jem.151.3.628 |
0.456 |
|
| 1980 |
Strassmann G, Eshhar Z, Mozes E. Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGu)-poly(DLAla)--poly(LLys). I. Expression of the genetic defect at two phases of the immune process. The Journal of Experimental Medicine. 151: 265-74. PMID 6766173 DOI: 10.1084/Jem.151.2.265 |
0.39 |
|
| 1980 |
Eshhar Z, Apte RN, Löwy I, Ben-Neriah Y, Givol D, Mozes E. T-cell hybridoma bearing heavy chain variable region determinants producing (T,G)-A--L-specific helper factor. Nature. 286: 270-2. PMID 6157102 DOI: 10.1038/286270A0 |
0.522 |
|
| 1980 |
Moshly-Rosen D, Fuchs S, Eshhar Z. Monoclonal antibodies against defined determinants of acetylcholine receptor. Febs Letters. 106: 389-92. PMID 91535 DOI: 10.1016/0014-5793(79)80538-4 |
0.348 |
|
| 1979 |
Eshhar Z, Strassmann G, Waks T, Mozes E. In vitro and in vivo induction of effector T cells mediating DTH responses to a protein and a synthetic polypeptide antigen. Cellular Immunology. 47: 378-89. PMID 90558 DOI: 10.1016/0008-8749(79)90347-2 |
0.5 |
|
| 1979 |
Bergman Y, Blatt C, Eshhar Z, Haimovich J. The Differences In Structure Between Secreted And Cell Surface Membrane Immunoglobulins Cell Biology and Immunology of Leukocyte Function. 245-252. DOI: 10.1016/B978-0-12-569650-0.50037-1 |
0.395 |
|
| 1975 |
Eshhar Z, Order SE, Katz DH. Ferritin, a Hodgkin's disease associated antigen. Proceedings of the National Academy of Sciences of the United States of America. 71: 3956-60. PMID 4139706 DOI: 10.1073/Pnas.71.10.3956 |
0.347 |
|
| 1975 |
Wekerle H, Eshhar Z, Lonai P, Feldman M. Thymus-derived rat lymphocyte receptor for cell surface antigens is a nonserologically defined product of the major histocompatibility gene complex. Proceedings of the National Academy of Sciences of the United States of America. 72: 1147-51. PMID 1079346 DOI: 10.1073/pnas.72.3.1147 |
0.301 |
|
| 1974 |
Eshhar Z. Specificity of heterologous antisera to components solubilized from rat thymocyte membranes. European Journal of Immunology. 3: 668-73. PMID 4589167 DOI: 10.1002/Eji.1830031103 |
0.328 |
|
| 1971 |
Eshhar Z, Gafni M, Givol D, Sela M. Solubilization of lymphocyte and thymocyte antigens by a reversible chemical modification European Journal of Immunology. 1: 323-329. PMID 4945634 DOI: 10.1002/Eji.1830010504 |
0.378 |
|
| Show low-probability matches. |